Aim:
To describe the clinico-epidemiological profile, metabolic risk factors, and treatment outcomes of patients with chronic liver disease (CLD) at a tertiary care center in Ajman, UAE.

Material and methods:
149 individuals with confirmed CLD were included in a descriptive five-year retrospective study. Descriptive statistics (frequencies and percentages) were utilized for analyzing demographic data, lifestyle variables, metabolic comorbidities, and clinical outcomes.

Results:
The male-to-female ratio in the cohort was 3.7:1, with a significant male preponderance (78.5%; n=117). In particular, most patients (91.3%) were under 60, with those under 40 making up the biggest group (46.3%; n=69). The Eastern Mediterranean Region was the place of origin for more than half of the participants (55.7%). In terms of lifestyle risk factors, 32.9% of respondents smoked, and 24.2% reported drinking alcohol (14.1% now, 10.1% previously). Although only 8.1% were classified as obese (BMI ≥30 kg/m²), 84.6% had abnormal BMI (overweight or obese). Fatty liver (41.6%), diabetes mellitus (38.9%), dyslipidaemia (37.6%), and hypertension (36.2%) were among the significant metabolic comorbidities. Nearly half (49.0%) of patients had incomplete or poor clinical outcomes to medications, whereas 51.0% had "good" results.

Conclusions:
This tertiary-care cohort found a predominance of economically productive males who were affected by CLD, who also exhibited a high prevalence of metabolic risk factors. Organs of obesity and diabetes have highlighted the regional influence of metabolic (MAD) liver disease. To optimise the outcome of patients who have these diseases, there is an urgent need for early screening and comprehensive management of metabolic risk factors.